14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial by Diacon, Andreas H, Prof, Dawson, Rodney, MD, von Groote-Bidlingmaier, Florian, MD, Symons, Gregory, MBChB, Venter, Amour, NatDipTech, Donald, Peter R, Prof, van Niekerk, Christo, MD, Everitt, Daniel, MD, Winter, Helen, PhD, Becker, Piet, PhD, Mendel, Carl M, MD, Spigelman, Melvin K, MD

Get full text

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, part... by Dawson, Rodney, MD, Diacon, Andreas H, MD, Everitt, Daniel, Dr, van Niekerk, Christo, MD, Donald, Peter R, MD, Burger, Divan A, MCom, Schall, Robert, PhD, Spigelman, Melvin, MD, Conradie, Almari, MPh, Eisenach, Kathleen, PhD, Venter, Amour, NatDipMicr, Ive, Prudence, FCP[SA], Page-Shipp, Liesl, MBBCh, Variava, Ebrahim, MD, Reither, Klaus, MD, Ntinginya, Nyanda E, MD, Pym, Alexander, MD, von Groote-Bidlingmaier, Florian, MD, Mendel, Carl M, MD

Get full text

A Side Chain at Position 48 of the Human Immunodeficiency Virus Type-1 Protease Flap Provides an Additional Specificity Determinant by Moody, Mark D., Pettit, Steve C., Shao, Wei, Everitt, Lorraine, Loeb, Daniel D., Hutchison, Clyde A., Swanstrom, Ronald

Get full text